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Abstract
Background
The failure of DNA vaccination in humans, in contrast to its efficacy in some species, is
unexplained. Observational and interventional experimental evidence suggests that DNA
immunogenicity may be prevented by binding of human serum amyloid P component
(SAP). SAP is the single normal DNA binding protein in human plasma. The drug (R)-1-[6-
[(R)-2-carboxypyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC, miride-
sap), developed for treatment of systemic amyloidosis and Alzheimer’s disease, depletes
circulating SAP by 95–99%. The proof-of-concept HIV-CORE 003 clinical trial tested
whether SAP depletion by CPHPC would enhance the immune response in human volun-
teers to DNA vaccination delivering the HIVconsv immunogen derived from conserved sub-
protein regions of HIV-1.
Methods
Human volunteers received 3 intramuscular immunizations with an experimental DNA vac-
cine (DDD) expressing HIV-1-derived immunogen HIVconsv, with or without prior depletion
of SAP by CPHPC. All subjects were subsequently boosted by simian (chimpanzee) adeno-
virus (C)- and poxvirus MVA (M)-vectored vaccines delivering the same immunogen. After
administration of each vaccine modality, the peak total magnitudes, kinetics, functionality
and memory subsets of the T-cell responses to HIVconsv were thoroughly characterized.
Results
No differences were observed between the CPHPC treated and control groups in any of the
multiple quantitative and qualitative parameters of the T-cell responses to HIVconsv, except
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that after SAP depletion, there was a statistically significantly greater breadth of T-cell speci-
ficities, that is the number of recognized epitopes, following the DDDC vaccination.
Conclusions
The protocol used here for SAP depletion by CPHPC prior to DNA vaccination produced
only a very modest suggestion of enhanced immunogenicity. Further studies will be required
to determine whether SAP depletion might have a practical value in DNA vaccination for
other plasmid backbones and/or immunogens.
Trial registration
Clinicaltrials.gov NCT02425241
Introduction
Parenteral injection of naked DNA encoding pathogen or cancer-derived immunogens is a
highly desirable approach to vaccination but, for unknown reasons, it is not efficacious in
some species including humans. Serum amyloid P component (SAP) is the single normal
human plasma protein that binds avidly to DNA under physiological conditions [1]. Studying
different animal species, we found a complete concordance between the efficacy of DNA vacci-
nation and either the complete absence of SAP or the presence of SAP that does not bind
strongly to DNA. For example, mice respond well to DNA vaccination and have SAP that
binds DNA very weakly [2]. However, transgenic mice expressing human SAP lost potent
murine immune responses to DNA vaccination and this inhibition was completely abrogated
when the transgenic mice were treated with (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-
hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC, miridesap) [3, 4], the SAP-depleting drug
[5]. In order to investigate whether human SAP might interfere with the immunogenicity of
DNA vaccination in humans, we conducted a phase I/IIa clinical trial of DNA vaccination in
subjects receiving infusion of CPHPC to deplete their circulating SAP at the time of each injec-
tion of DNA.
To tackle the enormous genetic plasticity of the human immunodeficiency virus type 1
(HIV-1), we pioneered a strategy, which focuses vaccine-elicited responses on the most con-
served regions of the HIV-1 proteome [6]. The first generation HIV-1 conserved immunogen,
HIVconsv [7], was presented to the immune system in the form of genetic vaccines using plas-
mid DNA, engineered non-replicating simian adenovirus ChAdV-63 and non-replicating
poxvirus modified vaccinia virus Ankara (MVA) [8]. The pSG2.HIVconsv DNA, ChAdV63.
HIVconsv and MVA.HIVconsv vaccines have been tested in a series of clinical trials in human
volunteers and shown to be safe and the last two highly immunogenic [8–12]. Clinical lots of
these vaccines were readily available for administration to human volunteers in the present
study, which aimed to improve the immunogenicity of the plasmid DNA vaccine component.
Materials and methods
The HIV-CORE 003 trial
The phase I/IIa HIV-CORE 003 trial was conducted in London, UK between October 2013
and February 2016. The trial was approved by the West London National Research Ethics Ser-
vice (NRES) Committee (Ref: 13/LO/0090) and by the UK Medicines and Healthcare products
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Regulatory Agency (Ref: 2012-004052-11). The study was conducted according to the princi-
ples of the Declaration of Helsinki (2008) and complied with the International Conference on
Harmonization Good Clinical Practice guidelines. All volunteers gave written informed con-
sent before participation. Tissue samples were stored and used in compliance with the UK
Human Tissue Act 2004 and with approval from local NRES.
Study population, vaccines, regimens and randomization
Forty healthy, HIV-1-negative adult male volunteers at low risk of HIV-1 infection were
enrolled (Fig 1) with mean (SD, range) age in years of 26 (6, 19–44) and including the follow-
ing ethnicities: 24 white British, 6 white other, 3 white Irish, 2 Indian, 1 Pakistani, 1 other
Asian, 1 mixed background. They each received experimental vaccines expressing the first-
generation HIV-1 conserved region-derived immunogen, HIVconsv (Fig 2A) [7], which was
delivered using plasmid DNA as pSG2.HIVconsv (D), engineered non-replicating simian ade-
novirus as ChAdV63.HIVconsv (C) and non-replicating poxvirus modified vaccinia virus
Ankara as MVA.HIVconsv (M) combined into heterologous regimens (Fig 2B). Construction
and manufacture of the vaccines were previously described [8, 10, 13]. We confirmed that
human SAP binds avidly to the vaccine plasmid DNA with Kd estimated from the binding iso-
therm as ~150 nM. All vaccine doses were administered by intramuscular needle injection. At
the outset, subjects were randomized to one of two groups cD or pD to receive an intravenous
Fig 1. CONSORT flow diagram of the HIV-CORE 003 trial. All CPHPC-treated volunteers completed the study protocol. Among the 20 volunteers allocated
to the placebo Group, 2 volunteers were lost to follow-up of whom 1 discontinued vaccinations.
https://doi.org/10.1371/journal.pone.0197299.g001
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infusion of CPHPC at 40 mg/hour in the experimental group or saline in the placebo control
group, respectively, before each dose of 4 mg of vaccine DNA. The DNA was injected 24 hours
after the infusion started and the infusion was terminated 2 hours later. The trial was initially
designed to compare the cDcDcDC (Groups 1a; n = 4) and pDpDpDC (Group 2a; n = 3)
regimens, however, following recruitment of the first 7 volunteers, it was modified to the
cDcDcDCM (Group 1b; n = 16) and pDpDpDCM (Group 2b; n = 17) regimens seeking to fur-
ther amplify, with the additional MVA.HIVconsv boost, any differences in immunogenicity
between the two groups. This Protocol modification was approved by the ethics committee,
Fig 2. Vaccine immunogen HIVconsv and the design of the HIV-CORE 003 trial. (A) Schematic representations of the HIVconsv immunogen and six pools
P1-P6 of a total of 199 overlapping peptides used for the detection of the human vaccine-elicited T-cell responses. HIVconsv is a chimaeric protein assembled
from 14 highly conserved regions of the HIV-1 proteome, the HIV-1 protein origins of which are colour-coded below. (B) Volunteers in the phase I/IIa
HIV-CORE 003 trial were randomized into Group 1 for depletion of serum amyloid P component (SAP) by a 26-hour infusion of drug CPHPC, or Group 2
receiving saline infusion alone as placebo, whereby the DNA was injected after 24 hours of infusion. All volunteers were boosted with non-replicating
recombinant virus vaccines expressing the same HIVconsv immunogen as indicated. cD–pSG2.HIVconsv DNA with CPHPC infusion prior to DNA
administration; pD–pSG2.HIVconsv with placebo infusion prior to DNA; C–non-replicating simian (chimpanzee) adenovirus-vectored vaccine ChAdV63.
HIVconsv; and M–non-replicating poxvirus-vectored vaccine MVA.HIVconsv. The number of volunteers recruited into each study group is indicated.
https://doi.org/10.1371/journal.pone.0197299.g002
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Power calculations for the group size
Power calculations were based on immunogenicity data obtained in trial HIV-CORE 002,
group DDDCM [8], and calculated for 20 participants in each group in trial HIV-CORE 003.
Thus, at 0–12 weeks (after DDD), whereby the mean ± SD peak response in HIV-CORE 002
was 73 ± 67 spot-forming units (SFU)/106 PBMC, we had 96% power to detect a 10-fold in-
crease. At 12–20 weeks (after DDDC), whereby the mean ± SD peak response was 1644 ± 1287
SFU/106 PBMC, we had 86% power to detect a 2.3-fold increase. Finally, at 21–22 weeks (after
DDDCM), whereby the mean ± SD peak response was 3285 ± 2091 SFU/106 PBMC, we had
80% power to detect a 1.58-fold increase. Note, that the induced frequencies of specific T cells
in HIV-CORE 002 were the highest published frequencies of vaccine-elicited T cells in the
field of HIV-1 vaccines using subunit genetic vaccines and so it was not reasonable to expect
huge increases from the DDDC and DDDCM peak responses. For comparison, the STEP
study using three administrations a HAdV-5-vectored vaccine induced between 136–686 SFU/
106 PBMC [14].
Isolation and cryopreservation of PBMC
Phlebotomy was performed as described before [15]. Blood was collected into heparinized
vacutainers (Becton Dickinson) and processed within 6 hours. Isolated PBMC were cryopre-
served using standard procedures [16].
Peptides and antigens
HIVconsv-derived 15-mer peptides overlapping by 11 amino acids and spanning the entire
HIVconsv protein (Ana-Spec, San Jose, USA) were reconstituted to 10–40 mg/ml in DMSO
and diluted to working stock solutions of 4 mg/ml in PBS as described previously [15].
Ex vivo IFN-γ ELISPOT assay
Freshly isolated PBMCs were used in an IFN-γ ELISPOT assay as described previously [15,
17]. Pre-wetted ELISPOT plate membranes (S5EJ044I10; Merck Millipore) were coated over-
night at 4˚C with anti-IFN-γ antibody (10 μg/ml in PBS; clone 1-D1K; Mabtech), washed with
PBS and blocked with R10 (RPMI 1460 supplemented with 10% FBS, 2 mM L-glutamine, 10
mM HEPES, 1 mM sodium pyruvate and penicillin-streptomycin antibiotics; Sigma Aldrich)
for 1 hour at 37˚C. The PBMC were plated out at 2x105 cells/well in 50 μl. For HIVconsv, trip-
licate well were used for six peptide pools P1-P6, 1.5 μg/ml per peptide. Six negative no-peptide
control wells with R10 supplemented with 0.45% DMSO served as the background negative
control. Cells cultured with 10 μg/ml PHA (Sigma Aldrich) or a pool of FEC (influenza virus,
Epstein-Barr virus and human cytomegalovirus) known epitope peptides at 1 μg/ml each in
triplicates were used as an internal positive control. Cell line NKL served as an external positive
control for a consistent number of SFU independent of stimulation across different days and
assay plates. The cells were incubated overnight at 37˚C in 5% CO2. Spots were visualised
using biotin-conjugated anti-IFN-γ mAb followed by alkaline phosphate-conjugated streptavi-
din (both from Mabtech) and the colour was developed using substrate BCIP/NBTPlus (Mab-
tech). The reaction was stopped after 5 min by washing under the tap. The plates were air
dried overnight and the spots were counted using an AID ELISpot Reader and version 5.0 soft-
ware (AID GmbH). Median number of SFU in no-peptide wells was subtracted from test wells
and the results were presented as median net SFU/106 PBMC.
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Cultured IFN-γ ELISPOT assay
Frozen PBMC from volunteers were thawed and expanded in vitro with peptides plus IL-2
before being subjected to an IFN-γ ELISPOT assay. Short-term cell lines (STCL) were gener-
ated from all volunteers at the end of the pSG2.HIVconsv DNA vaccinations, the visit of
ChAdV63.HIVconsv administration, by re-stimulation of the cells with each of the six peptide
pools P1-P6 at 1.5 μg/ml per peptide in the presence of rhIL-7 at 25 ng/ml. The cells were
maintained in culture and supplemented with recombinant human IL-2 at 100 IU/ml on days
3 and 7. After 10 days, the SCTL were washed, re-cultured without IL-2 for a minimum of 24
hours and then assayed for IFN-γ release in an ELISPOT assay as described above.
Luminex assay
The Luminex assay is a multiplex bead array that measures, in a single sample of culture super-
natant, the production by vaccine-elicited T cells of multiple cytokines and chemokines after
restimulation of the cells by specific-peptides. The procedures were described previously [15].
Cryopreserved PBMCs from three time points (pre-immune, peak pSG2.HIVconsv DNA and
peak ChAdV63.HIVconsv) were thawed and adjusted to 5 x 106 cells/ml in R10 containing
either a pool of all HIVconsv peptides at 1.5 μg/ml per peptide, Staphylococcus enterotoxin B
(SEB; Sigma-Aldrich) at 1.0 μg/ml, or medium alone as a negative control and anti-CD28 and
anti-CD49d mAbs both at 1 μg/ml in a final volume of 200 μl per well. The plates were incu-
bated for 48 hours at 37˚C, 5% CO2, and 150 μl of supernatant was removed from each well
and stored at -80 oC until use [18]. A human pre-mixed multi-analyte kit (Magnetic Luminex
screening assay, R & D Systems Ltd) was used to measure the following analytes; IFN-γ,
TNF-α, IL-2, IL-4, IL-6, IL-10, IL-13, IL-17A, SDF-1α (CXCL12), IP-10 (CXCL10), MIP-1α
(CCL3), MIP-1β (CCL4), RANTES (CCL5), Granzyme B and MIG (CXCL9). The culture
supernatants were diluted 1:1 and assayed in duplicate according to the kit instructions. Con-
centrations detected in unstimulated wells were used as background controls. The plate was
read using Luminex 200 and XPONENT software.
Polychromatic flow cytometry for memory subsets
PBMCs were thawed, incubated with 5 μl of the HLA-A02:01/YQYMDDLV tetramer (NIH
Tetramer Core Facility) conjugated to PE for 10 min at room temperature, followed by the
addition of 100 μl of a mastermix of anti-membrane marker mAbs containing LIVE/DEAD
fixable aqua stain (Molecular Probes, Invitrogen), CD3 ECD (Beckman Coulter), CD4 BV605
and CCR7 Pacific blue (Biolegend), CD8 Alexa Fluor 700, CD14 PE-Cy7, CD16 PE-Cy7,
CD19 PE-Cy7, CD45RA APC, CD57 FITC, TIGIT PerCP-eFluor710, PD-1 APC-eFluor780
(eBiosciences) and CD27 Qdot 655 (Life Technologies). The cells were incubated at 4˚C for a
further 20 min, washed and fixed with 1% paraformaldehyde in PBS prior to running on an
LSRII flow cytometer (Becton-Dickinson).
Statistics
Statistical analyses were carried out using GraphPad Prism 6.0d. ELISPOT and Luminex
results were assumed to be non-Gaussian in distribution, thus non-parametric tests were used
throughout and medians (range) are shown. Area-under-curve (AUC) values were determined
for the response of each volunteer within each group and analyzed using the Kruskal-Wallis
test with post-hoc Dunn’s Multiple Comparison Test. For comparison of the peak and breadth
of responses to peptide pools, significance was determined by the Mann Whitney test. Two-
tailed P values were used and P values of less than 0.05 were considered statistically significant.
Effect of SAP depletion on DNA vaccination
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Results
Safety and tolerability
All administrations of experimental vaccines and intravenous infusions of CPHPC were well
tolerated. There were no serious adverse events. There were comparable numbers of non-seri-
ous adverse events adverse events in the CPHPC and placebo groups (Table 1).
SAP depletion
At the time when the DNA vaccine was administered, the serum SAP concentration, measured
by electroimmunoassay [19], was always below the 1 mg/l lower limit of detection in all the
CPHPC recipients. All other serum samples from these subjects and from the recipients of the
normal saline placebo infusion, contained SAP concentrations within the reference range [19].
The overall range of serum concentration of SAP in all subjects in the study when not receiving
CPHPC was 15–65 mg/l, with mean ± SD of 31 ± 5 mg/l in the placebo group and 31 ± 8 mg/l
in the CPHPC group.
SAP depletion did not produce a statistically significant increase in T-cell
induction
An ex vivo IFN-γ ELISPOT assay on freshly isolated PBMCs was employed for detection of
any effects that the SAP depletion could have on the efficiency of DNA vaccine priming and
subsequent boosts with virus-vectored vaccines. One hundred and ninety nine 15-mer pep-
tides overlapping by 11 amino acids (15/11) spanning the HIVconsv protein were arranged
into six peptide pools P1-P6 (Fig 2A) and used to enumerate HIVconsv-specific T cells to
assess the overall magnitude (as the sum of the 6 pool frequencies) and breadth (number of
Table 1. Non-serious adverse events.
Disorder SAE CPHPC Placebo
Cardiac Hypertension 1/20 (5.00%) 0/20 (0.00%)
Blood & lymphatics Enlarged lymph node in neck 0/20 (0.00%) 1/20 (5.0%)
General Headache 4/20 (20.00%) 7/20 (35.00%)
Fatigue 2/20 (10.00%) 5/20 (25.00%)
Insomnia 1/20 (5.00%) 1/20 (5.00%)
Pain 1/20 (5.00%) 0/20 (0.00%)
Dizziness 0/20 (0.00%) 1/20 (5.00%)
Fever 0/20 (0.00%) 2/20 (10.00%)
Rigors 0/20 (0.00%) 2/20 (10.00%)
Gastrointestinal Diarrhoea 1/20 (5.00%) 0/20 (0.00%)
Dysphasia 2/20 (10.00%) 1/20 (5.00%)
Nausea 1/20 (5.00%) 2/20 (10.00%)
Vomiting 0/20 (0.00%) 1/20 (5.00%)
Anorexia 0/20 (0.00%) 1/20 (5.00%)
Renal & urinary Abnormal odour 0/20 (0.00%) 1/20 (5.00%)
Skin & subcutaneous Rash 2/20 (10.00%) 2/20 (10.00%)
Musculoskeletal Injection site reaction 9/20 (45.00%) 12/20 (60.00%)
Myalgia 7/20 (35.00%) 8/20 (40.00%)
Neck stiffness 0/20 (0.00%) 1/20 (5.00%)
Infections & infestations Coryzal symptoms 0/20 (0.00%) 2/20 (10.00%)
Total All 13/20 (65.00%) 16/20 (80.00%)
https://doi.org/10.1371/journal.pone.0197299.t001
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recognized pools) of the vaccine-elicited responses. Of the total of 520 samples tested, 11 or
2.1% failed the quality control. The overall kinetics of the elicited responses throughout the
vaccination and follow-up periods for the SAP-depleted and untreated subjects showed very
similar patterns (Fig 3A). This observation was confirmed by the area under curve (AUC)
analysis of 13 volunteers in each group, for whom a complete data set was available. AUC was
carried out over the entire time of the study and following each vaccine modality separately:
the respective median AUCs for the CPHPC and placebo groups were 15 and 80 for pSG2.
HIVconsv DNA (week 0–12), 2520 and 2355 for ChAdV63.HIVconsv (week 0–16), and 15460
and 14780 for MVA.HIVconsv (week 0–20) (Fig 3B). Following the DNA vaccinations with
and without SAP depletion, we also failed to observe any differences for the six individual
pools of the HIVconsv peptides (Fig 3C). Next we evaluated the peak IFN-γ ELISPOT assay
frequencies of HIVconsv-specific T cells after each vaccine modality administration and,
again, for the CPHPC and placebo groups, the respective median (range) frequencies were 45
(5–220) and 48 (0–810) induced by pSG2.HIVconsv DNA, 1130 (40–6215) and 835 (135–
2785) induced by ChAdV63.HIVconsv, and 4020 (1440–9870) and 3345 (830–20305) follow-
ing MVA.HIVconsv, which were not statistically separable (Fig 3D). We also assessed whether
or not the SAP-depleted DNA priming affected the proliferative capacity of the induced T cells
by enumerating the HIVconsv-specific T cells following a 10-day peptide pool-expansion cul-
tured pre-immune and week 9 PBMCs. Once again, SAP depletion did not translate into
increased proliferative capacity of HIVconsv-specific T cells (Fig 3E). Finally, we analysed the
number of pools that individuals were able to mount T-cell responses against in parallel and
found significantly broader responses after the ChAdV63.HIVconsv vaccination for the SAP-
depleted group, whereby the SAP-depleted and placebo vaccine recipients responded to
median (range) of 6 (0–6) and 4.5 (1–6) peptide pools (P = 0.044 in unpaired Mann-Whitney
test) (Fig 3F) and 10 vs 4 volunteers responded to 6 pools, respectively (Fig 3G). Overall, fol-
lowing depletion of the SAP from human blood prior to intramuscular DNA administration,
we were unable to detect improved induction of T-cell responses with the exception of signifi-
cantly broader responses at only one point of the vaccination protocol, directly after the sub-
jects had received DDDC.
SAP depletion did not affect the vaccine-elicited T-cell functionality or
memory subtypes
T cells can only contribute to the body’s defence if they exert their effector functions effectively
and in a timely fashion. To assess any possible effects of the CPHPC treatment prior to DNA
priming on the functionality of the HIVconsv-vaccine induced cellular responses, volunteers’
cryopreserved and thawed PBMCs were incubated with peptide pools P1-P6 for 48 hours and
the tissue culture supernatants were analyzed using a multiplex bead array quantifying produc-
tion of 15 cytokines and chemokines. These measurements were carried out for pre-immune,
peak DNA and peak ChAdV63.HIVconsv samples. Overall, varied levels of analytes were
detected, but the two trial Groups could not be separated (Fig 4). Six individuals, 4 in the
CPHPC and 2 in the placebo groups, had HLA-A02:01-positive tissue type, which allowed us
to carry out a highly sensitive evaluation of memory subtypes of their CD8+ T cells recognizing
HIV-1 Pol-derived epitope YQYMDDLYV using HLA-A02:01/YQYMDDLYV peptide tetramers.
In a polychromatic flow analysis, all six vaccine recipients developed a tetramer-reactive CD8+
T cells, which were structured into naïve (CD45RAhiCCR7hiCD27hi), central memory
(CD45RAloCCR7hiCD27hi), transitional memory (CD45RAloCCR7loCD27hi), effector memory
(CD45RAloCCR7loCD27lo) and terminally differentiated (CD45RAhiCCR7loCD27lo) T cells.
No tetramer-reactive populations stained for the programmed cell death protein 1 (PD-1)/
Effect of SAP depletion on DNA vaccination
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Fig 3. DNA priming of human T-cell responses with and without SAP depletion. Volunteers received heterologous vaccine
regimens, which included priming with DNA either preceded or not by depletion of SAP. The vaccines were as follows: cD–pSG2.
HIVconsv DNA after a 24-hour infusion of SAP-depleting CPHPC and additional 2-hour infusion after DNA administration (pink);
pD–pSG2.HIVconsv DNA with 26-hour infusion of saline as placebo (green); C–simian adenovirus ChAdV63.HIVconsv; and M–
poxvirus MVA.HIVconsv. All vaccines were delivered by intramuscular needle injection. Vaccine-induced T cells were enumerated in
Effect of SAP depletion on DNA vaccination
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CD279 and T-cell immune receptor with Ig and ITIM domains (TIGIT) inhibitory markers.
Again, we were unable to detect any outstanding differences between the SAP-depleted and
placebo groups (Fig 5). Thus, depletion of circulating SAP prior to intramuscular needle
administration of plasmid DNA, had no obvious quantitative or qualitative effect on priming
of transgene-specific T cells nor did it influence subsequent boosts with simian adenovirus- or
poxvirus MVA-vectored vaccines.
Discussion
Enhancement of the immunogenicity of DNA vaccines in humans, making them effective in
clinical practice, is highly desirable and there is compelling experimental animal evidence that
depletion of human SAP might be helpful. Availability of the experimental SAP-depleting
drug, CPHPC (now known by its recently awarded WHO International Non-Proprietary
Name, miridesap) at University College London [5], and of experimental GMP vaccines,
including one vectored by plasmid DNA [8], in Oxford University, uniquely enabled us to test
this idea in humans. Infusion of CPHPC for 24 hours before each injection of the DNA vaccine
reduced circulating SAP, as expected, to less than 1 mg/l. Multiple parameters of DNA vac-
cine-primed T cells were compared in the SAP-depleted and control groups: kinetics of
appearance, frequency at peak, proliferative capacity, ability to produce intercellular signalling
molecules and structure of memory subtypes. However, only the breadth of response, that is
the number of different epitopes that T cells as a population recognize at any one time, reached
statistical significance (P = 0.044) favouring the SAP-depleted recipients. This was observed
only after the DNA prime-simian adenovirus boost regimen (DDDC), but not after DNAalone
(DDD), and it was no longer detected after the MVA boost (DDDCM).
After vaccinating the first 7 volunteers with DDDC, we amended the immunization proto-
col by adding another rather strongly boosting vaccine modality MVA in the hope that any
minor differences achieved during the DNA priming phase would be amplified. We have
learnt since and here that a strongly boosting vaccine may have the opposite effect; rather than
amplifying differences, it blurs them and masks them [20]. For that reason, we focused our
search for effects on the vaccine-elicited T-cell responses on the period after DDD priming
and before the simian adenovirus boost. Nevertheless, neither cultured IFN-γ ELISPOT assays
nor profiling of functional molecules produced following a cognate peptide stimulation in
vitro yielded any statistically separable results between the CPHPC- and placebo-treated
groups.
We conclude that depletion of SAP with the regimen adopted here did not appreciably
improve the immunogenicity of the naked DNA encoding the HIVconsv antigen. Our hypoth-
esis may thus be wrong. However, the strong rationale provided by the experimental animal
findings, that created the hypothesis, still remains and the present suggestion of a possible
effect on breadth of immune response hints that it may be valid. There are several possible
a fresh ex vivo (A-D and F) or following a 10-day expansion (E) IFN-γ ELISPOTs assay using 6 peptide pools P1-P6 spanning the
HIVconsv immunogen. (A) Total frequencies were calculated as the sum of T cells responding to 6 pools of peptides P1-P6. The times
of vaccine administration are indicated below the graphs. (B) Comparison of AUC using group median T-cell frequencies for each
time point in the CPHPC (n = 13) and placebo (n = 13) groups. Only volunteers with full a data set were used. (C) Peak responses to
individual pools P1-P6 elicited by plasmid DNA (week 0–8) are shown. (D) Peak T-cell frequencies induced following plasmid pSG2.
HIVconsv DNA (week 0–8), ChAdV63.HIVconsv (week 8–12) and MVA.HIVconsv (week 16–20). (E) The proliferative capacity
determined as the frequencies of HIVconsv-specific T cells following a 10-day restimulation of samples from week 12. (F) Breadth of
induced T-cell responses defined as the number of recognized peptides pools (out of 6) following the ChAdV63.HIVconsv boost,
whereby breadth for all (left) and HLA-A02:01-positive subjects receiving CPHPC (n = 11) or placebo (n = 9) (right) are shown. Data
are presented as median with range. (G) Bars depict the number of responders to 0–6 peptide pools P1-P6. The median, interquartile
and total range, and individual values are plotted for each visit (A, C, D, and E).
https://doi.org/10.1371/journal.pone.0197299.g003
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Fig 4. Functionality of vaccine-induced human T cells primed using plasmid DNA in the presence or absence of SAP. The functionality of T cells elicited
with (pink) and without (green) CPHPC treatment prior to the DNA administration was assessed in the Luminex assay measuring the concentration of
secreted signalling molecules into the culture supernatant by volunteers’ PBMC following a 48-hour HIVconsv peptide restimulation. The functionality of
specific T cells was determined after pSG2.HIVconsv DNA (CV1 and PV1), ChAdV63.HIVconsv (CV2 and PV2) and MVA.HIVconsv (CV3 and PV3)
administration. At no point and for no measured cytokine were the values statistically separable between the CPHPC and placebo recipients (Mann-Witney
test).
https://doi.org/10.1371/journal.pone.0197299.g004
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reasons for this marginal outcome. We excluded one possibility, namely that SAP does not
bind the particular DNA immunogen we used, but the contrary possibility remains: the inhibi-
tory potency of SAP may be so great that even the trace amount of residual SAP after CPHPC
infusion was sufficient to block DNA immunogenicity. We may thus have used insufficient
CPHPC to achieve our desired objective. Given the potential value to human health of effica-
cious DNA vaccines, and the possible development of an oral dosing form of CPHPC that
would make practical SAP depletion a viable proposition, further clinical studies with more
effective SAP depletion ahead of DNA vaccination would be worthwhile. In the present trial,
CPHPC was infused for just 24 hours before DNA injection and continued for only 2 hours
thereafter, based on logistical feasibility in this volunteer study. While circulating SAP was pro-
foundly depleted, we do not know whether SAP was adequately removed from the extracellular
compartment of the tissues, specifically the intramuscular sites of DNA injection. The binding
of SAP to DNA is very avid and we do not know how much SAP may be sufficient to suppress
the capacity of the DNA to transfect cells and trigger expression of the encoded protein immu-
nogen. Investigation of the effects of SAP depletion on immunogenicity of DNA vaccines
delivering different immunogens, if they are available, will also be of considerable interest.
Meanwhile, the experimental vaccines that were employed in the HIV-CORE 003 trial were
the first generation of HIV-1 T-cell vaccines [7], which focuses elicited T-cell responses on
highly functional conserved regions of the HIV-1 proteome common to most global variants,
Fig 5. HLA-A02:01/YQY tetramer-aided analysis of human CD8+ T-cell memory subsets. For six HLA-A02:01-positive vaccine recipients, frozen and
thawed PBMCs from indicated time point were analyzed for memory subsets defined as TN−naïve T cells (CD45RAhiCCR7hiCD27hi). TCM—central memory
(CD45RAloCCR7hiCD27hi), TTM—transitional memory (CD45RA
loCCR7loCD27hi), TEM—effector memory (CD45RA
loCCR7loCD27lo), and TTD—terminally
differentiated (CD45RAhiCCR7loCD27lo). See S1 Fig for the gating strategy. D–pSG2.HIVconsv DNA; C–ChAdV63.HIVconsv; M–MVA.HIVconsv. The
number next to the regimen indicates weeks after administration of the last vaccine.
https://doi.org/10.1371/journal.pone.0197299.g005
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which are the most vulnerable parts of HIV-1 [6]. These vaccines have now been used in 8 clin-
ical trials in UK, Europe and Africa. They have proven the concept that, in-natural-infection
subdominant protein epitopes can be taken out of the context of the whole proteins/virus and
delivered by an in-human potent regimen such as the simian adenovirus-MVA sequential
administration to induce robust HIV-1-specific T-cell responses. These can inhibit in vitro
replication of viruses of 4 major global clades [8, 9, 11, 21] and, in HIV-1-positive patients,
provided a preliminary signal of controlling HIV-1 viremia after pausing antiretroviral treat-
ment [12]. As we demonstrated previously, having induced robust CD8+ T-cells response in
the volunteers of this trial provides a further opportunity to identify novel subdominant, but
potentially protective HIV-1 epitopes [22]. Accumulation of knowledge about protective epi-
topes may in turn help predict early success or failure of future candidate T-cell vaccines
against HIV-1.
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